KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash & Current Investments (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Cash & Current Investments for 16 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 53.42% year-over-year to $1.3 billion, compared with a TTM value of $1.1 billion through Jun 2025, down 57.41%, and an annual FY2025 reading of $1.3 billion, down 53.42% over the prior year.
  • Cash & Current Investments was $1.3 billion for Q4 2025 at Alnylam Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $2.7 billion in Q4 2024 and bottomed at $536.3 million in Q1 2022.
  • Average Cash & Current Investments over 5 years is $1.5 billion, with a median of $1.1 billion recorded in 2025.
  • The sharpest move saw Cash & Current Investments soared 372.72% in 2021, then crashed 67.6% in 2022.
  • Year by year, Cash & Current Investments stood at $2.4 billion in 2021, then plummeted by 63.27% to $870.7 million in 2022, then fell by 6.16% to $817.1 million in 2023, then soared by 228.77% to $2.7 billion in 2024, then crashed by 53.42% to $1.3 billion in 2025.
  • Business Quant data shows Cash & Current Investments for ALNY at $1.3 billion in Q4 2025, $1.1 billion in Q2 2025, and $1.6 billion in Q1 2025.